Business context and reporting period
Pulse Biosciences, Inc. (Nasdaq: PLSE) filed this Form 8-K on October 7, 2026, to report a clinical-study milestone. The filing does not cover a financial reporting period.
Clinical-study update
The company announced that the NANOPULSE-AF study reached its target of 164 evaluable patients across 15 clinical sites. The study evaluates the nPulse Cardiac Catheter System for drug-resistant, symptomatic, paroxysmal atrial fibrillation. It is a prospective, multicenter, non-randomized IDE pivotal investigation; the first patients were treated in April 2026.
Primary safety and effectiveness endpoints are to be assessed at 6 and 12 months after ablation. The filing reports enrollment progress, not clinical results.
Financial metrics and material changes
The filing provides no revenue, profit, cash-flow, margin, debt, liquidity, or other financial metrics, and no comparable-period financial results. It does not report a financial change associated with the enrollment milestone.
Outlook, risks, and contingencies
No financial guidance or outlook is provided. Study outcomes remain pending assessment at the stated follow-up points; the filing does not provide results or a clear timeline for reporting them.
Key facts for investors to verify
- Whether the study meets its primary safety and effectiveness endpoints at 6 and 12 months.
- When the company reports follow-up results and whether any enrollment or evaluability changes are disclosed.
- Any subsequent regulatory, clinical, or financial updates related to the nPulse Cardiac Catheter System.